NAPA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that results of a clinical study of Pyratine-6(TM) have been featured in the February issue of the Journal of Drugs in Dermatology.
The study was implemented to determine the efficacy and tolerance of topical Pyratine-6(TM) over 12 weeks for improving the baseline clinical signs and symptoms of photodamaged facial skin. In the single-arm longitudinal study with observations at 2, 4, 8, and 12 weeks, efficacy and safety were evaluated by clinical observations, digital photography, transepidermal water loss (TEWL), skin capacitance, and silicon replicas at each time point.
The study concluded that treatment with Pyratine-6(TM) over 12 weeks improves roughness and skin moisturization in 2 weeks compared to baseline and mottled hyperpigmentation (brown spots and discoloration) and fine wrinkles in 4 weeks compared to baseline. Reduction in facial erythema was observed as early as two weeks.
Dr. Jerry McCullough, lead investigator in the study stated, "In addition to the encouraging results in the treatment of photodamaged skin overall, another important finding is the significant reduction in erythema at 2 weeks and the additional reductions at weeks 4, 8, and 12. To my knowledge, this is the first report to show reduced erythema associated with use of a topical non-prescription therapeutic product."
"We are delighted to have made this important treatment available through leading plastic surgeons and dermatologists across the country", said Frank Massino, Chairman and Chief Executive Officer of Senetek, "and look forward to extending the significant clinical findings for Pyratine-6(TM) through additional ongoing clinical investigation."
About Dr. McCullough:
Dr. Jerry McCullough is a pioneer in the field of Der
|SOURCE Senetek PLC|
Copyright©2008 PR Newswire.
All rights reserved